Radiation responsive molecules derived from horse chestnuts aid cancer imaging

NewsGuard 100/100 Score

Research at The City College of New York shows that cancer imaging can be simplified by a photonic process utilizing molecules derived from horse chestnuts. The study with potential to better detect the presence of cancer is led by George John, professor in City College's Division of Science, in collaboration with Jan Grimm, a physician scientist at Sloan Kettering Institute who is also affiliated with Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.

The team has developed a radiation responsive esculin-derived molecular gel, that is both scintillating and fluorescent, to enhance the optical photon output in image mapping for cancer imaging.

Esculin, or Æsculin, is a coumarin glucoside that naturally occurs in the horse chestnut, a plant extract. It is beneficial to circulatory health.

A challenge currently in cancer imaging is that optical imaging of radiotracers through Cerenkov light (the Grimm lab is one of the leading labs in this field) often produces light that is typically low in intensity and blue-weighted (greatly scattered and absorbed in vivo). It is therefore imperative to increase or shift the photon flux for improved detection.

The gel has been developed to address this challenge.

"Tailoring biobased materials to synthesize thixotropic thermo-reversible hydrogels offers image-aiding systems which are not only functional but also potentially economical, safe, and environmentally friendly," said John.

"The possibility of developing a topical application from the gel makes this innovation an attractive potential improvement to current techniques of cancer imaging with Cerenkov light," added Grimm.

A Fellow of Britain's Royal Society of Chemistry, John's research is rooted in the idea that innovation can be inspired by nature to develop economical and green technologies for a sustainable future.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer